Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

HS-20094

Stage Phase 3Stale

Sponsor Regeneron Pharmaceuticals

Route injection

Mechanism A Phase 3, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Olatorepatide, a GLP-1/GIP Receptor Agonist, in Participants Living With Overweight or Obesity Without Diabetes (RISE-1)

Sources

registry, as of 2026-10-26Stale

https://clinicaltrials.gov/study/NCT07896265

Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Regeneron Pharmaceuticals. Enrollment 3000. Conditions Overweight or Obesity Without Diabetes. This study will test olatorepatide (study drug) to determine whether it can help treat overweight or obesity. In this study we will test how safe and how well olatorepatide works compared to placebo in people who are overweight or obese but do not have diabetes. The study is lo

ClinicalTrials.gov NCT07896265 protocol and results modules

registry, as of 2026-06-08Stale

https://clinicaltrials.gov/study/NCT06839664

A Study of HS-20094 in Chinese Adults With Overweight or Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Jiangsu Hansoh Pharmaceutical Co., Ltd.. Enrollment 604. Conditions Overweight; Obesity. The main purpose of this study is to assess the Efficacy and safety of HS-20094 in overweight and obese patients. The study will last up to approximately 52 weeks.

ClinicalTrials.gov NCT06839664 protocol and results modules

registry, as of 2026-11-06

https://clinicaltrials.gov/study/NCT07685808

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes. Overall status RECRUITING. Phases PHASE2. Lead sponsor Regeneron Pharmaceuticals. Enrollment 360. Conditions Overweight or Obesity. This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing side effects, as well as how the

ClinicalTrials.gov NCT07685808 protocol and results modules

registry, as of 2026-09-21Stale

https://clinicaltrials.gov/study/NCT07830329

Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity. Overall status NOT_YET_RECRUITING. Phases PHASE2. Lead sponsor Regeneron Pharmaceuticals. Enrollment 300. Conditions Hidradenitis Suppurativa. This study will test an experimental Regeneron drug called olatorepatide ("study drug") to see if it can help treat Hidradenitis Suppurativa (HS). In this study, olatorepatide is being tested in people with HS and living with overweight or obesity to see if it helps improve thei

ClinicalTrials.gov NCT07830329 protocol and results modules

registry, as of 2026-06-04Stale

https://clinicaltrials.gov/study/NCT06118021

A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese Subjects. Overall status COMPLETED. Phases PHASE2. Lead sponsor Jiangsu Hansoh Pharmaceutical Co., Ltd.. Enrollment 200. Conditions Overweight and Obesity. This is a study of HS-20094 in participants with overweight and obesity. The main purpose is to learn more about how HS-20094 affects body weight. The study period including 4-12 weeks dose titration and 12-20 weeks maintain treatment and 6 weeks follow up.

ClinicalTrials.gov NCT06118021 protocol and results modules

registry, as of 2026-06-17Stale

https://clinicaltrials.gov/study/NCT07431086

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor Regeneron Pharmaceuticals. Enrollment 120. Conditions Overweight or Obesity. This study will test olatorepatide (study drug) to determine how safe and effective this drug is and how easily your body can accept this drug without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity. The study wil

ClinicalTrials.gov NCT07431086 protocol and results modules

registry, as of 2025-07-10Stale

https://clinicaltrials.gov/study/NCT07057674

A Study of HS-20094 in Overweight or Obese Participants. Overall status RECRUITING. Phases PHASE1. Lead sponsor Jiangsu Hansoh Pharmaceutical Co., Ltd.. Enrollment 144. Conditions Overweight or Obesity. This is a multicenter, randomized, open-label, parallel clinical study to evaluate the bioequivalence of the HS-20094 MDV pen and AI pen in overweight or obese subjects.

ClinicalTrials.gov NCT07057674 protocol and results modules

Studies

RISE-1

Registry NCT07896265

Phase Phase 3

Status Not yet recruiting

Enrollment 3000

Start 2026-11-18

Primary completion 2028-12-19

Study completion 2029-01-23

Catalyst Primary completion. 2028-12-19. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Olatorepatide-Dose 1

Comparator placebo

Population Overweight or Obesity Without Diabetes

Olatorepatide-Dose 2

Comparator placebo

Population Overweight or Obesity Without Diabetes

Olatorepatide-Dose 3

Comparator placebo

Population Overweight or Obesity Without Diabetes

Placebo-Dose 1

Population Overweight or Obesity Without Diabetes

Placebo-Dose 2

Population Overweight or Obesity Without Diabetes

A Study of HS-20094 in Chinese Adults With Overweight or Obesity

Registry NCT06839664

Phase Phase 3

Status Completed

Enrollment 604

Start 2024-11-16

Primary completion 2026-01-04

Study completion 2026-01-30

Catalyst Primary completion. 2026-01-04. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

HS-20094 5mg

Dose 5mg

Comparator placebo

Population Overweight; Obesity

HS-20094 10mg

Dose 10mg

Comparator placebo

Population Overweight; Obesity

HS-20094 15mg

Dose 15mg

Comparator placebo

Population Overweight; Obesity

Placebo

Population Overweight; Obesity

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

Registry NCT07685808

Phase Phase 2

Status Recruiting

Enrollment 360

Start 2026-07-28

Primary completion 2028-01-21

Study completion 2028-01-21

Catalyst Primary completion. 2028-01-21. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Olatorepatide arm 1

Comparator placebo

Population Overweight or Obesity

Olatorepatide arm 2

Comparator placebo

Population Overweight or Obesity

Olatorepatide arm 3

Comparator placebo

Population Overweight or Obesity

Olatorepatide arm 4

Comparator placebo

Population Overweight or Obesity

Olatorepatide arm 5

Comparator placebo

Population Overweight or Obesity

Matching Placebo arm 6

Population Overweight or Obesity

Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity

Registry NCT07830329

Phase Phase 2

Status Not yet recruiting

Enrollment 300

Start 2026-10-30

Primary completion 2028-11-24

Study completion 2028-12-22

Catalyst Primary completion. 2028-11-24. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Olatorepatide

Comparator placebo

Population Hidradenitis Suppurativa

Placebo

Population Hidradenitis Suppurativa

A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese Subjects

Registry NCT06118021

Phase Phase 2

Status Completed

Enrollment 200

Start 2023-10-16

Primary completion 2024-08-13

Study completion 2024-08-13

HS-20094 5mg

Dose 5mg

Regimen once weekly

Weeks 12

Population Overweight and Obesity

HS-20094 10mg

Dose 10mg

Regimen once weekly

Weeks 12

Population Overweight and Obesity

HS-20094 15mg

Dose 15mg

Regimen once weekly

Weeks 12

Population Overweight and Obesity

HS-20094 20mg

Dose 20mg

Regimen once weekly

Weeks 12

Population Overweight and Obesity

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US

Registry NCT07431086

Phase Phase 2

Status Active, not recruiting

Enrollment 120

Start 2026-03-16

Primary completion 2026-11-13

Study completion 2026-12-18

Catalyst Primary completion. 2026-11-13. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

General Cohort

Population Overweight or Obesity

Subgroup Cohort

Population Overweight or Obesity

A Study of HS-20094 in Overweight or Obese Participants

Registry NCT07057674

Phase Phase 1

Status Recruiting

Enrollment 144

Start 2025-04-16

Primary completion 2026-02-04

Study completion 2026-05-29

Catalyst Primary completion. 2026-02-04. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

T1 group

Regimen once weekly

Weeks 4

Population Overweight or Obesity

T2 group

Regimen once weekly

Weeks 4

Population Overweight or Obesity